New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:20 EDTMDVN, CBST, ALKS, SLXP, JAZZ, AUXL, NPSP, HSP, AKRX, UTHRLeerink names top 10 acquisition candidates in biopharma
Leerink believes partnership and acquisition activity will remain a key feature of news flow and excess returns for investors in the biopharma industry during 2014 and into 2015. The firm's top 10 acquisition candidates in the space are: Alkermes (ALKS), Akorn (AKRX), Akorn (AUXL), Cubist (CBST), Hospira (HSP), Jazz Pharmaceuticals (JAZZ), Medivation (MDVN), NPS Pharmaceuticals (NPSP), Salix (SLXP) and United Therapeutics (UTHR).
News For ALKS;AKRX;AUXL;CBST;HSP;JAZZ;MDVN;NPSP;SLXP;UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
12:58 EDTSLXPPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
10:51 EDTSLXPOptions with increasing implied volatility
Options with increasing implied volatility: CLDN CMG CREE AMZN ISRG MAC UA VMW SLXP
09:06 EDTMDVNMedivation price target raised to $144 from $123 at William Blair
Subscribe for More Information
07:53 EDTMDVNMedivation reported strong, positive results, says JMP Securities
JMP Securities says that the results of a study comparing Medivation's Xtandi to bicalutamide, the market leading prostate cancer medication, were strong and positive for Medivation. The firm continues to expect Xtandi to prove to be superior to bicalutamide. It expects Xtandi to generate $8B in worldwide revenue and raised its price target on Medivation to $143 from $126 while keeping an Outperform rating on the shares.
07:39 EDTMDVNMedivation price target raised to $142 from $125 at Brean Capital
Brean Capital raised its price target on Medivation to $142 from $125 following the presentation of additional Phase 2 TERRAIN trial data in metastatic castration-resistant prostate cancer and final OS data from the Phase 3 PREVAIL trial in chemo-naive mCRPC. The firm remains optimistic by consistent and positive data and reiterated its Buy rating on Medivation shares.
07:02 EDTMDVNMedivation price target raised to $148 from $130 at JPMorgan
Subscribe for More Information
March 24, 2015
07:07 EDTMDVNAstellas Pharma and Medivation report data from Phase 2 Terrain trial
Subscribe for More Information
March 23, 2015
09:03 EDTHSPPfenex announces early HSR clearance for collaboration with Hospira
Subscribe for More Information
March 20, 2015
16:33 EDTSLXPStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
10:18 EDTSLXPOptions with decreasing implied volatility
Options with decreasing implied volatility: NKTR FOLD RUSL RSX ORCL GES CTRP SLXP WSM SPXS
09:34 EDTAKRXAkorn management to meet with William Blair
Subscribe for More Information
07:06 EDTAKRXAkorn launches Phenylephrine HCl Ophthalmic Solution
Subscribe for More Information
March 19, 2015
10:42 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
March 18, 2015
13:05 EDTJAZZJazz Pharmaceuticals management to meet with Piper Jaffray
Subscribe for More Information
10:21 EDTAKRXHigh option volume stocks:
Subscribe for More Information
10:00 EDTSLXPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:32 EDTAKRXAkorn restatement minor, shares attractive, says Jefferies
Subscribe for More Information
07:12 EDTAKRXAkorn shares should recover 'strongly,' says William Blair
William Blair believes shares of Akorn "should recover strongly" with the uncertainty of the annual filing delay being lifted last night. The firm notes management reiterated that the restated financial estimates for 2014 do not affect 2015 guidance. Blair still expects Akorn's 2015 to be a year of "significant cash flow, opportunistic acquisitions, pipeline approvals, and strong growth despite clobetasol competition." It lowered its price target for shares to $58 from $60 and keeps an Outperform rating on the name.
07:12 EDTAUXLInnocoll appoints James Tursi, M.D., as Chief Medical Officer
Subscribe for More Information
05:45 EDTSLXPSalix downgraded to Hold from Buy at Jefferies
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use